Season 3 of Surfing The NASH Tsunami

S3-E41.3 - Improving NASH Clinical Trials By Reducing Screen Fail Rates

S3-E41.3 – Improving NASH Clinical Trials By Reducing Screen Fail Rates

The “Band” (Jörn Schattenberg, Stephen Harrison, Louise Campbell and Roger Green) gets back together with no other guests to talk NASH Clinical Trials, improving screen fail rates, finding more patients and, generally, what has changed since Jörn co-authored his 2020 article on the NASH Clinical Trial Graveyard.

S3-E41.2 - Improving NASH Clinical Trials By Reducing Screen Fail Rates

S3-E41.2 – Improving NASH Clinical Trials By Reducing Screen Fail Rates

The “Band” (Jörn Schattenberg, Stephen Harrison, Louise Campbell and Roger Green) gets back together with no other guests to talk NASH Clinical Trials, improving screen fail rates, finding more patients and, generally, what has changed since Jörn co-authored his 2020 article on the NASH Clinical Trial Graveyard.

S3-E41.1 - Improving NASH Clinical Trials By Reducing Screen Fail Rates

S3-E41.1 – Improving NASH Clinical Trials By Reducing Screen Fail Rates

The “Band” (Jörn Schattenberg, Stephen Harrison, Louise Campbell and Roger Green) gets back together with no other guests to talk NASH Clinical Trials, improving screen fail rates, finding more patients and, generally, what has changed since Jörn co-authored his 2020 article on the NASH Clinical Trial Graveyard.

S3-E40.5 - From the Vault: Why Cirrhosis Matters In Clinical Trial Strategy

S3-E40.5 – From the Vault: Why Cirrhosis Matters In Clinical Trial Strategy

This episode discusses the unique role NASH cirrhosis studies can play in clinical trial design, particularly in the transition from biopsy as gold standard to a post-biopsy world. Stephen Harrison starts this conversation by discussing why we focus on NASH cirrhosis and goes on to review the recent presentation of results from the REVERSE study on obeticholic acid. Jörn Schattenberg and Mazen Noureddin add their perspectives to the conversation.

S3-E40.4 - Challenges of Alcohol Screening in Fatty Liver Disease

S3-E40.4 – Challenges of Alcohol Screening in Fatty Liver Disease

Co-authors Michelle Long and Mazen Noureddin join Louise Campbell and Roger Green to discuss their recent publication on Best Practice in lean NASH. This conversation focuses on the challenges of alcohol screening when assessing a patient for Fatty Liver disease.

S3-E40.3 - Importance of Early Diagnosis in Lean NASH

S3-E40.3 – Importance of Early Diagnosis in Lean NASH

Co-authors Michelle Long and Mazen Noureddin join Louise Campbell and Roger Green to discuss their recent publication on Best Practice in lean NASH. This conversation focuses on why early diagnosis is so important when dealing with Lean NASH.

S3-E40.2 - A Simple Diagnostic Algorithm for Lean NASH

S3-E40.2 – A Simple Diagnostic Algorithm for Lean NASH

Co-authors Michelle Long and Mazen Noureddin join Louise Campbell and Roger Green to discuss their recent publication on Best Practice in lean NASH. This conversation focuses on the elegant one-page diagnostic algorithm they recommend for diagnosing Lean NASH in “normal” BMI patients with signs of liver disease.

S3-E40 - Best Practices in Lean NASH: Authors Provide Back Story

S3-E40 – Best Practices in Lean NASH: Authors Provide Back Story

Co-authors Michelle Long and Mazen Noureddin join Louise Campbell and Roger Green to discuss their recent Clinical Practice Update in Gastroenterology titled “Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review.”

S3-E39.5 - From The Vault: Early, Accurate Patient Information Matters

S3-E39.5 – From The Vault: Early, Accurate Patient Information Matters

In this conversation from September 2021, Anthony Villiotti of NASH kNOWledge joins Louise Campbell and Roger Green to discuss his “biggest story of the summer:” two publications, on demonstrating that NASH prevalence and incidence may be far higher than we believe and another demonstrating how limited public knowledge about NASH is today.

S3-E39.4 - Patient Follow-Up Challenges in Modeling NASH Diagnostics

S3-E39.4 – Patient Follow-Up Challenges in Modeling NASH Diagnostics

Ian Rowe’s decision curve model does an excellent job of modeling the success rate and cost effectiveness of modeling early NASH diagnosis. However, as Louise Campbell points out, simply getting the patient diagnosed does not mean therapeutic success, which has implications for the early diagnosis model and broader patient management issues.

S3-E39.3 - NASH challenges: Early Diagnosis and NASH Patient Management

S3-E39.3 – NASH Challenges: Early Diagnosis & NASH Patient Management

Ian Rowe, Louise Campbell and Roger Green discuss two issues in NASH patient management: the number of patients that are told they have Fatty Livers not to worry about treating it, and the general challenges in treating patients whose NASH is part of a constellation of metabolic diseases.

S3-E39.2 - What An Early Decision Models Tells Us About Fibrosis & Metabolic Diseases

S3-E39.2 – What An Early Decision Models Tells Us About Fibrosis & Metabolic Diseases

Professor Ian Rowe and Louise Campbell share opinions and insights on the need to improve diagnosis of clinically relevant fibrosis and how some of these issues are reflected in the decision curve model Ian has built with Richard Parker. discusses the issues that led him and his colleague Richard Parker to create a model to determine the most cost effective approach to early diagnosis of clinically significant fibrosis, along with a description of the model they built.

S3-E39.1 - Creating An Early Diagnosis NASH Decision Model

S3-E39.1 – Creating An Early Diagnosis NASH Decision Model

Professor Ian Rowe discusses the issues that led him and his colleague Richard Parker to create a model to determine the most cost effective approach to early diagnosis of clinically significant fibrosis, along with a description of the model they built.

S3-E39 - Reviewing a Decision Model for Early NASH Diagnosis

S3-E39 – Reviewing a Decision Model for Early NASH Diagnosis

Ian Rowe joins the Surfers to share a poster he co-authored at this year’s EASL International Liver Congress. The poster shares a decision model Professor Rowe developed to analysis the cost effectiveness of five different strategies for early NASH diagnosis.

S3-E38.5 - From the Vault: NAIL-NIT tackles NAS Score Challenges

S3-E38.5 – From the Vault: NAIL-NIT tackles NAS Score Challenges

From February of this year, Stephen Harrison and Mazen Noureddin join Jörn Schattenberg, Louise Campbell and Roger Green to discuss the formation of the new NAIL-NIT consortium, led by Stephen and Mazen. This conversation focuses on the specific challenges inherent in the NAS scores.

S3-E38.3 - From the Vault: Learning Fibrosis at Paris NASH

S3-E38.3 – From the Vault: Learning Fibrosis at Paris NASH

From September 2021, Stephen Harrison and Jörn Schattenberg lead the Surfers on a deep dive into the fibrosis section of the recent Paris NASH conference. The conversation focuses on fibrosis and the role of stellate cells in fibrogenesis.

S3-E38.1 - From the Vault: Why NASH Drug Trials Fail

S3-E38.1 – From the Vault: Why NASH Drug Trials Fail

Our 2nd anniversary look in the Vault starts with Jörn Schattenberg’s first episode as a featured guest, a 2020 episode reviewing his article on why NASH drug trials fail. One key focus was the proper design and use of Phase 2 trials.

S3-E37.5 - The Need to Focus on NASH Cirrhosis Patients

S3-E37.5 – The Need to Focus on NASH Cirrhosis Patients

Antaros Medical co-founder and Chief Scientific Officer Lars Johansson joined the Surfers to explore opportunities to improve scientific insight surrounding NASH cirrhosis and cirrhosis patient care. This conversation sums up much of the previous discussion, with the conclusion that as diagnostic technologies and drugs in development improve, the need to communicate better with patients remains pivotal for successful therapies.

S3-E37.4 - The "Pincer Movement" In Cirrhosis Technology: Patient Support vs High-End MedTech

S3-E37.4 – The “Pincer Movement” In Cirrhosis Technology: Patient Support vs High-End MedTech

Antaros Medical co-founder and Chief Scientific Officer Lars Johansson joined the Surfers to explore opportunities to improve scientific insight and patient care surrounding NASH cirrhosis. This conversation focuses on a “pincer movement” in the technology necessary to support cirrhosis patients: low-end technology to foster better patient communication and education, and high-end medical technology to diagnose, stage and treat the disease faster and more accurately.

S3-E37.3 - Where Is the Next Cirrhosis Breakthrough?

S3-E37.3 – Where Is the Next Cirrhosis Breakthrough?

Antaros Medical co-founder and Chief Scientific Officer Lars Johansson joined the Surfers to explore opportunities to improve scientific insight and patient care surrounding NASH cirrhosis. This conversation asks where we will find the next major breakthrough in treating cirrhosis patients.

S3-E37.1 - Cirrhosis Screening and Diagnostic Tests

S3-E37.1 – Cirrhosis Screening and Diagnostic Tests

Antaros Medical co-founder and Chief Scientific Officer Lars Johansson joined the Surfers to explore opportunities to improve scientific insight and patient care surrounding NASH Cirrhosis Screening and Diagnostic Tests.

S3-E36.5 - REGENERATE Redux: Clearing The Finish Line?

S3-E36.5 – REGENERATE Redux: Clearing The Finish Line?

Stephen Harrison leads the rest of the Surfers (Jörn Schattenberg, Louise Campbell and Roger Green), through a discussion of Intercept Pharmaceuticals’ July 7 press release on re-analysis of the REGENERATE trial evaluating obeticholic acid (OCA) for treating of NASH fibrosis. This conversation asks (and attempts to answer) whether the REGENERATE reanalysis is likely to succeed in getting the drug approved.

S3-E36.4 - REGENERATE Redux: Other Obeticholic Acid (OCA) Questions

S3-E36.4 – REGENERATE Redux: Other Obeticholic Acid (OCA) Questions

Stephen Harrison leads the rest of the Surfers (Jörn Schattenberg, Louise Campbell and Roger Green), through a discussion of Intercept Pharmaceuticals’ July 7 press release on re-analysis of the REGENERATE trial evaluating obeticholic acid (OCA) for treating of NASH fibrosis. This conversation focuses on…

S3-E36.3 - REGENERATE Redux: Safety and Tolerability With Obeticholic Acid

S3-E36.3 – REGENERATE Redux: Safety and Tolerability With Obeticholic Acid

Stephen Harrison leads the rest of the Surfers (Jörn Schattenberg, Louise Campbell and Roger Green), through a discussion of Intercept Pharmaceuticals’ July 7 press release on re-analysis of the REGENERATE trial evaluating obeticholic acid (OCA) for treating of NASH fibrosis. This conversation focuses on safety and tolerability issues in this analysis. This is important because most observers believe it was the risk:benefit tradeoff analysis that led to the Complete Response Letter in 2020.

S3-E36.2 - REGENERATE Redux: What OCA Efficacy Results Mean For Patients

S3-E36.2 – REGENERATE Redux: What OCA Efficacy Results Mean For Patients

Stephen Harrison leads the rest of the Surfers (Jörn Schattenberg, Louise Campbell and Roger Green), through a discussion of Intercept Pharmaceuticals’ July 7 press release on re-analysis of the REGENERATE trial evaluating obeticholic acid (OCA) for treating of NASH fibrosis. This conversation focuses on the meaning of the efficacy results in this trial and what they imply for patient therapy.

S3-E36.1 - REGENERATE Redux: Obeticholic Acid (OCA) Efficacy

S3-E36.1 – REGENERATE Redux: Obeticholic Acid (OCA) Efficacy

Stephen Harrison leads the rest of the Surfers (Jörn Schattenberg, Louise Campbell and Roger Green), through a discussion of Intercept Pharmaceuticals’ July 7 press release on re-analysis of the REGENERATE trial evaluating obeticholic acid (OCA) for treating of NASH fibrosis. This conversation focuses on its basic efficacy results.

S3-E36 - REGENERATE Redux - Can OCA Succeed With New Data?

S3-E36 – REGENERATE Redux – Can OCA Succeed With New Data?

The Core Four (Stephen Harrison, Jörn Schattenberg, Louise Campbell, and Roger Green) review Intercept Pharmaceuticals’s recent press release on the new REGENERATE findings and ask whether these results are strong enough for OCA to gain approval in NASH fibrosis.

S3-E35.4 - Liver Science At ILC 2022: Commercial Benefit From the New Liver Science

S3-E35.5 – Liver Science At ILC 2022: Mid-Range Impact of Advances

Scott Friedman, Neil Henderson and Rachel Zayas join the Surfers to discuss a groundbreaking session from #ILC2022 discussing advances in what Liver Science can tell us about fibrosis. This conversation focuses on Roger Green’s final question, which asks for tangible changes that will ensue over the next 1-5 years as impact of advances in the liver science research processes and findings discussed in this episode.

S3-E35.2 - Liver Science At #ILC2022: The Interplay of Stellate Cell Dynamics and Hepatic Fibrosis

S3-E35.2 – Liver Science At ILC 2022: The Interplay of Stellate Cell Dynamics & Hepatic Fibrosis

Scott Friedman, Neil Henderson and Rachel Zayas join the Surfers to discuss a groundbreaking session from #ILC2022 discussing advances in what Liver Science can tell us about fibrosis. This conversation focuses on two abstracts that explore the stellate cell dynamics in the creation and resolution of fibrotic scars. Both of these rely on the kinds of single cell analyses that lie at the heart of much of Neil Henderson’s research.

S3-E35.1 - Liver Science at #ILC2022: Circadian Rhythm and Stellate Cells

S3-E35.1 – Liver Science at ILC 2022: Circadian Rhythm and Stellate Cells

Last month, roughly 5,000 liver community stakeholders gathered in London for the 2022 International Liver Congress (ILC 2022.) On Thursday afternoon, Scott Friedman chaired an abstract session discussing advances in the basic science of researching and understanding mechanisms surrounding fibrosis and stellate cells.

S3-E34.2 - #ILC2022 Looking Back: Other Thoughts on Resmetirom Presentations

S3-E34.2 – #ILC2022 Looking Back: Other Thoughts on Resmetirom Presentations

After Stephen Harrison shares key elements from two of his resmetirom presentations at #ILC2022, Jörn Schattenberg, Mazen Noureddin and Michelle Long share thoughts and questions about the presentation. After this, Jörn Schattenberg shares key points from his presentation of an assessment of accuracy of FIB-4 in 2,000 biopsy-confirmed patients in the resmetirom trials.

S3-E34 - #ILC2022 Wrap-Up 1: NASH Drug Development Excitement!

S3-E34 – #ILC2022 Wrap-Up 1: NASH Drug Development Excitement!

Michelle Long and Mazen Noureddin join the Surfers (including Stephen Harrison) for a wrap-up of the major stories of #ILC2022. Much of the episode focuses on NASH Drug Development, with side conversations about the value and challenges of relying on FIB-4 or, even worse, ALT in patient screening and diagnosis.

S3-E32.3 - ILC 2022 Looking Back: NASH Is a Complex Disease

S3-E32.3 – ILC 2022 Looking Back: NASH Is a Complex Disease

Last week, roughly 5,000 liver community stakeholders gathered in London for the 2022 International Liver Congress (#ILC2022,) the first major hepatology Congress to be held in person since the start of the pandemic (smaller, but very valuable, meetings like NASH-TAG, LiverCONNECT and Paris NASH have taken place with an in-person component, but the International Liver Congress and The Liver Meeting have not).

S3-E32.2 - ILC 2022 Looking Back: NAFLD and Quality-of-Life

S3-E32.2 – ILC 2022 Looking Back: NAFLD and Quality-of-Life

Last week, roughly 5,000 liver community stakeholders gathered in London for the 2022 International Liver Congress (#ILC2022,) the first major hepatology Congress to be held in person since the start of the pandemic (smaller, but very valuable, meetings like NASH-TAG, LiverCONNECT and Paris NASH have taken place with an in-person component, but the International Liver Congress and The Liver Meeting have not).

S3-E30.4 - Highlighting Intriguing ILC2022 Abstracts: Potential Uses of FIB-4

S3-E30.4 – Highlighting Intriguing ILC2022 Abstracts: Potential Uses of FIB-4

Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green identify some of what they believe will be key papers at #ILC2022. This conversation focuses largely on OS025 Non-invasive fibrosis scores as prognostic biomarkers of liver events, cardiovascular events and all-cause mortality in people with obesity and/or type 2 diabetes in the UK: a longitudinal cohort study.

S3-E30.2 - Highlighting Intriguing ILC2022 Abstracts: Elastography and the Importance of NAFLD Quality-of-Life Metrics

S3-E30.2 – Highlighting Intriguing ILC2022 Abstracts: Elastography and the Importance of NAFLD Quality-of-Life Metrics

Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green identify some of what they believe will be key papers at 3ILC2022. This conversation focuses on FRI100, which assessees the value of different tests in a real-world setting, and OS044, which explores general and disease-specific Quality-of-Life scores for patients with different levels of Fatty Liver disease against a control group with no disease.

S3-E30.1 - Highlighting Intriguing ILC2022 Abstracts: Machine Learning Identified NASH Biomarkers and a Cost-Effectiveness Study

S3-E30.1 – Highlighting Intriguing ILC2022 Abstracts: Machine Learning Identified NASH Biomarkers and a Cost-Effectiveness Study

Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green identify some of what they believe will be key papers at 3ILC2022. This conversation focuses on OS 097, which uses LITMUS Metacohort Data to identify the biomarkers that predict each of the four element of the NASH score best and FRI094, a study that evaluates the cost of community-based NAFLD screening for Type 2 Diabetes patients.

S3-E30 - Previewing #ILC2022: Focus on NITs and Patients

S3-E30 – Previewing #ILC2022: Focus on NITs and Patients

Jörn Schattenberg, Stephen Harrison, Louise Campbell and Roger Green discuss some of the most striking and important Fatty Liver-related abstracts to be presented at next week’s #ILC2022 meeting in London. Some key drug development papers are embargoed, but there were plenty of important works on NITs, quality-of-life and general patient issues for the group to discuss.

Subscribe for free. New podcasts Wednesday Evening / Thursday Morning.

Apple
Spotify
Google
Stitcher
Buzzsprout
YouTube
SoundCloud

Sponsoring Partnerships!

Sponsoring partnerships with SurfingMASH present a multifaceted avenue for companies seeking to amplify their brand presence and engage with targeted audiences.